KMT5A and ovarian carcinoma: To furthermore examine the potential for therapeutic targeting of KMT5A in clinical practice in the near future, we also treated MDA-MB-231 and 4T1 cells with a KMT5A-selective inhibitor, UNC0379, which has been evaluated to inhibit hepatocellular carcinoma and ovarian cancer progression and metastasis37,38.